U.S. regulations are too cautious. Europe has adopted a more sensible approach.

If the swine flu virus should continue to spread, or the infections worsen, rapid development of a vaccine could be our best protection.

We must make a concerted effort today to increase our capacity for timely development of safe, effective and innovative flu vaccines.

The United States' insufficient supply of H1N1 vaccines to inoculate our population demonstrates how poorly prepared we are to confront a pandemic.

We have made progress in pandemic preparedness, but we have a long way to go in ensuring a vibrant and responsive vaccine sector.

We must begin to make our plans more broad-based to encompass the most threatening of pandemic scenarios.

As Congress considers legislation that would allow imitative biological products, known as "biosimilars," to rely on the safety and efficacy data of original innovators, it must ensure that any provisions passed will foster, not stifle, discovery.

Targeted biotech drugs that attack specific biological molecules that cause disease are bringing new benefitsand fomentingpricing dynamics different from those of traditional drugs.